Asset Details
Do you wish to reserve the book?
Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement
Do you wish to request the book?
Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement
2009
Overview
Evidence clearly shows a chemopreventive effect for aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) on colorectal cancer and probably other cancer types; however, data on the risk–benefit profile for cancer prevention are insufficient and no definitive recommendations can be made. Aspirin has emerged as the most likely NSAID for use in chemoprevention because of its known cardiovascular benefit and available safety and efficacy data. Other traditional NSAIDs, particularly sulindac, and selective COX-2 inhibitors are now given to patients at high risk of colorectal cancer, although these drugs do not provide cardioprotection. More studies of aspirin and cancer prevention are needed to define the lowest effective dose, the age at which to initiate therapy, the optimum treatment duration, and the subpopulations for which the benefits of chemoprevention outweigh the risks of adverse side-effects. Although it might be possible to answer some of these questions with longer follow-up of existing clinical trials, randomised controlled trials with new study designs will be needed. Future projects should investigate the effects of aspirin treatment on multiple organ systems. Cancers of interest are colorectal, breast, prostate, lung, stomach, and oesophageal. The main side-effect of aspirin is peptic ulcers; therefore coadministration of aspirin with a proton-pump inhibitor is an attractive option and is under investigation in the AspECT trial.
Publisher
Elsevier Ltd,Elsevier Limited
Subject
Anti-Inflammatory Agents, Non-Steroidal - adverse effects
/ Anti-Inflammatory Agents, Non-Steroidal - therapeutic use
/ Breast Neoplasms - prevention & control
/ Colorectal Neoplasms - prevention & control
/ Digestive System Neoplasms - prevention & control
/ Female
/ Hematology, Oncology, and Palliative Medicine
/ Humans
/ Lung Neoplasms - prevention & control
/ Neoplasms - prevention & control
/ Ovarian Neoplasms - prevention & control
/ Risk
